

Director Profiles

Rob Thomas

Chairman and Non-executive Director *AM, BEc, MSAA, SF Fin*



Mr Thomas has a strong background in financial services and is a non executive director on a number of listed Healthcare companies in Australia and the United States. He has more than 35 years' experience in the securities industry with Potter Partners (now UBS), County Natwest and Citigroup. He is currently Chairman of Gragher Capital Securities and the NSW State Library. He is the immediate past non-executive Chairman of Heartware International Inc and remains a non-executive director of that company and is also a director of ASX listed REVA Medical Inc., Virgin Australia Limited and Biotron Limited. Rob holds a Bachelor of Economics from Monash University and is a fellow of the Securities Institute of Australia. He is also a Master Stockbroker and is a Fellow of the Institute of Company Directors.

Jackie Fairley

Chief Executive Officer *BSc, BVSc (Hons), MBA, GAICD*



Dr Jackie Fairley has more than 25 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006.

Jackie holds first class honours degrees in Science and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School where, as Dux of her final year, she was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. Jackie currently sits on the board of the Melbourne Business School, and is a past member of the Federal Government's Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also an advisor to the Carnegie Innovation Fund.

Richard A. Hazleton

Non-executive Director *BSchE, MSChE, HonDrEngr, HonDrCommSci*



Mr Hazleton is retired chairman and CEO of Dow Corning Corporation, a Michigan-based multinational producer of specialty chemicals and materials. Mr Hazleton began his Dow Corning career in 1965. He held numerous positions in engineering, manufacturing and finance, both in the US and Europe, before becoming CEO of the company in 1993, and Chairman of the Board of Directors and CEO in 1994. He retired in 2001. Mr Hazleton has served on the Boards of the American Chemistry Council and the Chemical Bank and Trust Company. He served as Chairman of the Board of DNT Inc. from 2004 until the company was acquired by Starpharma in October 2006. Hazleton holds bachelors and masters degrees in chemical engineering from Purdue University, and earned a master of business administration degree from Central Michigan University.

Zita Peach

Non-executive Director *BSc*



Ms Peach has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme (MSD), the Australian subsidiary of Merck Inc. She is currently the Managing Director and Executive Vice President, South Asia Pacific for Fresenius Kabi Australia, a leader in infusion therapy and clinical nutrition. Until recently Ms Peach was Vice President/Director, Business Development R&D for CSL, a position she held for ten years. Ms Peach is also a Non-Executive Director of the ASX-listed Vision Group Holdings.

Peter Turvey

Non-executive Director *BA/LLB, MAICD*



Mr Turvey recently retired from CSL as Executive Vice President Licensing for the R&D Division and Company Secretary after nearly two decades. Peter worked at CSL since 1992 in various roles including Group General Counsel, Company Secretary and Executive Vice President Licensing. He also played a key role in the transformation of CSL from a government owned enterprise to a global plasma and biopharmaceutical company, leading the management of CSL's intellectual property across CSL's global operations. During his time at CSL Peter was involved in many licensing deals including the Gardasil license to Merck & Co. He is also a member of the Board of Viralytics and a Principal of the Foursight Group.

Key Management Profiles

Jackie Fairley

Chief Executive Officer *BSc, BVSc (Hons), MBA, GAICD*



Dr Jackie Fairley has more than 25 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006.

Jackie holds first class honours degrees in Science and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School where, as Dux of her final year, she was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. Jackie currently sits on the board of the Melbourne Business School, and is a past member of the Federal Government's Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also an advisor to the Carnegie Innovation Fund.

Nigel Baade

Chief Financial Officer/Company Secretary *BCom, CPA, Grad Dip Arts (Development)*



Mr Baade is a CPA-qualified accountant with extensive experience in the pharmaceutical and biotechnology industries. Appointed to the position on 1 January 2009, he is responsible for the financial control and compliance of the Group. Mr Baade has experience in project and cost management of research activities, commercialisation of global business development opportunities, public and private equity raising and grant funding compliance. Prior to joining Starpharma as Financial Controller in 2006, he has held positions at Hagemeyer, Cerylid Biosciences, Faulding (Hospira) and UMT (Fonterra). He holds qualifications from University of Tasmania and Monash University.

Tony Eglezos

Vice President Business Development *BSc (Hons), PhD, MBA*



Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia. Most recently he was Director Commercial Operations, Pharmaceuticals and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his 7 years in business development with CSL, Tony's responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.

David Owen

Vice President Drug Discovery *BSc (Hons), PhD*



Dr Owen has extensive experience in medicinal chemistry and biochemistry, and in managing teams focused on commercially directed drug discovery. He has held several positions in the biotech industry including Mimotopes, Cerylid and Glykoz and gathered extensive international experience in biotechnology and pharmaceutical research and development. Since joining Starpharma David has driven the drug delivery programs by developing and executing a number of successful proof-of-concept studies. The results from these studies have led to a number of commercial partnerships such as Stiefel a GSK company, Lilly and AZ, as well as driving Starpharma's own internal drug delivery program focused on an improved dendrimer-docetaxel formulation.

Jeremy Paul

Vice President, Development and Regulatory Affairs *BSc (Hons), PhD*



Dr Paul heads up Starpharma's preclinical and clinical development programs and manages the company's interactions with international regulatory authorities. Jeremy also leads Starpharma's NIH-funded programs, and is responsible for successful collaborations with the company's many international research and commercial development partners. Key priorities include the advancement of the VivaGel stand-alone product through late-stage development, and the development of the coated condom product. Since joining Starpharma in 2001, Dr Paul's efforts have been integral to the advancement of the VivaGel® development program.

Filippa Shub

Director of Intellectual Property *Registered Patent and Trademark Attorney, B.Sc (Biol), M.Sc (PrIm), GDip IPLaw, MBA, FIPTA*



Ms Shub is a qualified Patent and Trade Mark Attorney with responsibility for managing the Intellectual Property assets of the Company. She has more than 20 years' experience in Research, Commercialisation and Intellectual Property. Before joining Starpharma Ms Shub worked with both legal firms and biotechnology companies in Australia and USA, including Davies, Collison Cave, Allens Arthur Robinson, Norwood Abbey and CSL.